Business Description
Rafael Holdings Inc
NAICS : 531110
SIC : 6519
520 Broad Street, Newark, NJ, USA, 07102
Description
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.98 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.7 | |||||
Beneish M-Score | -5.03 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.8 | |||||
3-Year EBITDA Growth Rate | -95.8 | |||||
3-Year EPS without NRI Growth Rate | -16.9 | |||||
3-Year FCF Growth Rate | -68 | |||||
3-Year Book Growth Rate | -6.7 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.26 | |||||
9-Day RSI | 62.34 | |||||
14-Day RSI | 60.51 | |||||
6-1 Month Momentum % | -29.48 | |||||
12-1 Month Momentum % | -94.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.51 | |||||
Quick Ratio | 3.51 | |||||
Cash Ratio | 3.34 | |||||
Days Sales Outstanding | 44.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.2 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1740.6 | |||||
Net Margin % | -3322.96 | |||||
ROE % | -120.49 | |||||
ROA % | -99.29 | |||||
ROIC % | -70.27 | |||||
ROC (Joel Greenblatt) % | -329.91 | |||||
ROCE % | -124.72 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.24 | |||||
PB Ratio | 0.46 | |||||
Price-to-Tangible-Book | 0.49 | |||||
EV-to-EBIT | -0.06 | |||||
EV-to-EBITDA | -0.06 | |||||
EV-to-Revenue | 2.02 | |||||
EV-to-FCF | -0.6 | |||||
Price-to-Net-Current-Asset-Value | 0.98 | |||||
Price-to-Net-Cash | 1.05 | |||||
Earnings Yield (Greenblatt) % | -1792.89 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:RFL
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 3.98 | ||
EPS (TTM) ($) | -7.06 | ||
Beta | 1.31 | ||
Volatility % | 70.38 | ||
14-Day RSI | 60.51 | ||
14-Day ATR ($) | 0.189999 | ||
20-Day SMA ($) | 2.1395 | ||
12-1 Month Momentum % | -94.89 | ||
52-Week Range ($) | 1.6 - 54.83 | ||
Shares Outstanding (Mil) | 24.03 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Rafael Holdings Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |